Prasugrel gains NICE approval

The UK's drug guidance body has endorsed the use of prasugrel (Efient) in patients with acute coronary syndromes who are undergoing percutaneous coronary intervention.

Prasugrel (Efient) prevents clot formation by binding to the P2Y12 ADP receptor on the surface of platelets, thereby inhibiting platelet activation and aggregation.
Prasugrel (Efient) prevents clot formation by binding to the P2Y12 ADP receptor on the surface of platelets, thereby inhibiting platelet activation and aggregation.

NICE guidance states that prasugrel can be used, in conjunction with aspirin, for the prevention of atherothrombotic events in individuals who:

  • need immediate primary percutaneous coronary intervention for ST-segment-elevation MI, or
  • developed stent thrombosis during clopidogrel treatment, or
  • have diabetes mellitus.

People already receiving prasugrel for acute coronary syndromes who do not meet these criteria can continue to receive the drug until it is appropriate to stop.

View Efient drug record

NICE guidance on prasugrel


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in